Zai Lab (ZLAB) announced that China’s National Medical Products Administration approved the new drug application for Cobenfy for the treatment of schizophrenia in adults. The NMPA’s approval of Cobenfy is supported by the results from a Phase 1 pharmacokinetics study conducted in China, the Phase 3 China study and data from three clinical studies.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB: